 Tumor reduction was observed in 83 5 of 6 of HPV16-positive relapsed or refractory checkpoint inhibitor naïve advanced cancer patients and 58 7 of 12 of HPV16-positive relapsed or refractory advanced cancer patients who have also failed checkpoint inhibitor therapy Tumor reduction was observed in 83 5 of 6 of HPV16-positive relapsed or refractory checkpoint inhibitor naïve advanced cancer patients and 58 7 of 12 of HPV16-positive relapsed or refractory advanced cancer patients who have also failed checkpoint inhibitor therapy 